BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Maccine Enters Singapore GLP Compliance Program


6/10/2009 12:12:42 PM

Singapore, 10 June 2009, Maccine, the preclinical contract research organisation, was this week confirmed on the Singapore Good Laboratory Practice (GLP) compliance program. The announcement followed a series of audits by the Singaporean national GLP monitoring authority alongside observers from countries of the Organisation for Economic Co-operation and Development (OECD).

Singapore is a provisional signatory to the OCED Mutual Acceptance of Data (MAD) agreement and there are a large number of GXP operations there already including many major pharmaceutical firms’ manufacturing and clinical operations.

Leigh Berryman, Maccine’s CEO and a certified GLP professional, commented on the successful audit “Maccine has been GLP compliant for some time and although we have already submitted studies to the FDA and other authorities almost half our customers are from OECD countries where this GLP framework is typical. This will certainly give confidence to those who have not yet visited us and convenience to those who do not have audit teams.”

Studies conducted at Maccine under full Quality Assurance control are those that are likely to be submitted as part of Investigational New Drug (IND) or Clinical Trial Authorisation (CTA) applications such as repeat dose toxicology studies and cardiovascular safety pharmacology.

Other safety pharmacology studies such as abuse liability assessment, that have historically not required GLP compliance, can also be conducted under GLP in the neuroscience centre at Maccine’s Singapore research site.

About Maccine:

Maccine is a Singapore based preclinical contract research organisation providing innovative discovery support and quality safety assessment services to the global biotech and pharma industry.

Read at BioSpace.com

Maccine
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES